Gargiulo et al. [22] analyzed the drug survival of interleukin inhibitors (IL-12/23, IL-17, and IL-23) for moderate-to-severe plaque psoriasis in a real-world, multicenter cohort of 5932 treatment courses. Here, IL17A is linked to psoriasis vulgaris.